Creating Intelligent Vaccines for Humanity

1
Creating Intelligent Vaccines for Humanity
2
Who we are

• Vaccine Development Company Founded in 2001
• Focusing on Vaccines for Viruses with High
  Genetic Variability
• HIV, Influenza, Hepatitis C, etc

• Based in Gatineau/Ottawa with 29 FTE
• Mainly technical/scientific ? 12 PhD
• Scrappy Bunch of Bootstrappers
• 2001-2006 1M total equity in seed financings
• Series A in Dec 2006 35.7M USD

3
VBI Leadership

• Executive Management
• Francisco Diaz-Mitoma, MD, PhD Founder and CEO
• 15 years of vaccine development mgmt experience
  as a physician/consultant
• Egidio Nascimento, CA - CFO
• 17 years of financing experience, most recently
  at Genome Canada
• Board of Directors
• Chair Jeff Leiden, MD, PhD, Clarus Ventures and
  former President of Abbott Pharmaceuticals
• Steve Gillis, PhD, ARCH Venture Partners and
  founder and former CEO of Corixa
• Scott Rocklage, PhD, 5AM Ventures and former
  Chairman CEO of Cubist and Nycomed
• Scientific Advisory Board
• Gary Nabel, Director NIH Vaccine Institute
• Mike Levine, Director Vaccine Research Center, U
  of Maryland
• Alex Sette, Director Immunology and Vaccine
  Center, U of San Diego
• Richard Ulevitch, Chairman Dept Immunology,
  Scripps
• Russ Middaugh, Formulation Research Center,
  University of Kansas

4
From Bootstrap to Bootstrap to Series A
5
External Environment
The Vaccine Boom! RPM Report, Sept 06
Vaccines Increasingly Interesting Merrill Lynch
Vaccine Market to Exceed 10B by 2007 Lehman
Brothers, April 2005
A Vaccine Development Renaissance LA Times,
Jan 2007
A Pipeline of New Vaccines Expected to Drive
Market Growth Nature Reviews, March 06
VBI Gets Shot In the Arm, Closes 35.7M USD
Ottawa, Citizen, Jan 07
Jeez, its about time! Undisclosed VBI
Executive, Jan 07
6
Early Partners Collaborators

• Public Health Agency of Canada
• National Research Council of Canada
• Economic Development Canada
• Investment Quebec
• Childrens Hospital of Eastern Ontario
• University of Ottawa
• Dalton Pharma

7
Thank you